Stelvio Ballanti
Overview
Explore the profile of Stelvio Ballanti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marra A, Santi A, Pucciarini A, Venanzi A, De Carolis L, Zaja F, et al.
Am J Hematol
. 2024 Jan;
99(3):497-501.
PMID: 38264797
Distinct outcomes of BRAF inhibition in BRAF-mutated hairy cell neoplasms with wild-type or mutant TP53, and alternative strategies to overcome mutant TP53.
2.
DAgostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, More S, Corradini P, et al.
Blood
. 2023 Dec;
143(7):592-596.
PMID: 38048557
The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRD-negative patients the ones at higher risk...
3.
Mina R, Petrucci M, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, et al.
Haematologica
. 2023 Nov;
109(5):1525-1534.
PMID: 37981892
High-dose melphalan plus autologous stem cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic stem cell (HSC) collection is...
4.
Perriello V, Falini L, Ruggeri L, Sorcini D, Ballanti S, Flenghi L, et al.
EJHaem
. 2023 May;
4(2):559-562.
PMID: 37206291
No abstract available.
5.
Trecarichi E, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, et al.
Int J Antimicrob Agents
. 2023 Apr;
61(6):106806.
PMID: 37030470
Bloodstream infections (BSI) caused by Gram-negative bacteria (GNB) in patients with hematological malignancies (HM) have been associated with high mortality rates, particularly with infections caused by antibiotic-resistant strains. A multicenter...
6.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al.
Lancet Oncol
. 2022 Dec;
24(1):64-76.
PMID: 36528035
Background: Patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities (HRCA) represent an unmet medical need. In the FORTE trial, lenalidomide and dexamethasone plus carfilzomib (KRd) induction resulted in...
7.
Perriello V, Falini L, Ruggeri L, Innocente A, Ballanti S, Costa C, et al.
Am J Hematol
. 2022 Nov;
98(1):212-219.
PMID: 36346356
No abstract available.
8.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, et al.
Front Oncol
. 2022 Aug;
12:890376.
PMID: 35924160
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRS ) and progression-free survival (PFS, PRS ) in 919 relapsed/refractory multiple myeloma (RRMM) patients...
9.
Saldi S, Perriello V, Falini L, Ruggeri L, Fulcheri C, Ciardelli S, et al.
Front Immunol
. 2022 Aug;
13:934700.
PMID: 35911683
CAR T cell therapy has transformed the salvage approach for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Maintaining disease control before CAR T cell infusion during product manufacturing (so-called bridging...
10.
Falini L, Venanzi A, Tini V, Innocente A, Ballanti S, Saldi S, et al.
Haematologica
. 2022 Jul;
108(1):290-294.
PMID: 35899391
No abstract available.